[Scoring system of late effects of radiations on normal tissues: the SOMA-LENT scale].
ABSTRACT Radiation tolerance of normal tissues remains the limiting factor for delivering tumoricidal dose. The late toxicity of normal tissues is the most critical element of an irradiation: somatic, functional and structural alterations occur during the actual treatment itself, but late effects manifest months to years after acute effects heal, and may progress with time. The optimal therapeutic ratio ultimately requires not only complete tumor clearance, but also minimal residual injury to surrounding vital normal tissues. The disparity between the intensity of acute and late effects and the inability to predict the eventual manifestations of late normal tissue injury has made radiation oncologists recognize the importance of careful patient follow-up. There is so far no uniform toxicity scoring system to compare several clinical studies in the absence of a "common toxicity language". This justifies the need to establish a precise evaluation system for the analysis of late effects of radiation on normal tissues. The SOMA/LENT scoring system results from an international collaboration. European Organization Treatment of Cancer (EORTC) and Radiation Therapy Oncology Group (RTOG) have created subcommittees with the aim of addressing the question of standardized toxic effects criteria. This effort appeared as a necessity to standardize and improve the data recording, to then describe and evaluate uniform toxicity at regular time intervals. The current proposed scale is not yet validated, and should be used cautiously.
- Radiotherapy and Oncology 05/1995; 35(1):1-3. · 4.52 Impact Factor
- Radiotherapy and Oncology 05/1995; 35(1):9-10. · 4.52 Impact Factor
- [show abstract] [hide abstract]
ABSTRACT: Radiation morbidity is as important as tumour control when determining the value of radiotherapy, but there is no internationally agreed system for the recording of morbidity. A scheme based upon the scoring of the elements which make up morbidity has been endorsed by a 2-day Workshop sponsored by the Medical Research Council and a system is now available for trial.Radiotherapy and Oncology 11/1989; 16(2):103-8. · 4.52 Impact Factor